Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2022
Reporting Period: Fourth quarter and fiscal year ended December 31, 2021
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results and an investor presentation. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) referenced within the document.
Material Changes
The filing announces the issuance of results of operations and financial condition for the period ended December 31, 2021. No specific material changes or comparative data are provided within the text of this 8-K; investors must refer to the attached exhibits for detailed performance analysis versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The company released an updated investor presentation on March 23, 2022, intended for use in meetings with investors.
Legal Disclaimer: The information furnished under Item 2.02 and Item 7.01, including the press release and investor presentation, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2021 financial figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated strategic outlook and operational milestones.
- Verify the company's cash position and burn rate, as these are critical for an emerging growth biotech firm but are not listed in this summary text.
- Confirm the status of the company's pipeline and any new partnerships mentioned in the referenced exhibits.